全文获取类型
收费全文 | 64篇 |
免费 | 13篇 |
专业分类
基础医学 | 12篇 |
临床医学 | 6篇 |
内科学 | 24篇 |
神经病学 | 6篇 |
特种医学 | 2篇 |
外科学 | 4篇 |
预防医学 | 4篇 |
药学 | 10篇 |
肿瘤学 | 9篇 |
出版年
2023年 | 3篇 |
2021年 | 6篇 |
2020年 | 8篇 |
2019年 | 6篇 |
2018年 | 6篇 |
2017年 | 7篇 |
2016年 | 3篇 |
2015年 | 3篇 |
2014年 | 6篇 |
2013年 | 3篇 |
2012年 | 2篇 |
2010年 | 1篇 |
2008年 | 1篇 |
2007年 | 1篇 |
2006年 | 2篇 |
2005年 | 4篇 |
2004年 | 4篇 |
2003年 | 2篇 |
2002年 | 2篇 |
2001年 | 1篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1993年 | 1篇 |
1986年 | 1篇 |
1973年 | 2篇 |
排序方式: 共有77条查询结果,搜索用时 35 毫秒
11.
Tacey R Greway A Smiell J Power D Kromminga A Daha M Casadevall N Kelley M 《Journal of immunological methods》2003,283(1-2):317-329
Rare cases of unexplained sudden severe anemia or red cell aplasia and resistance to recombinant human erythropoietin (rHuEPO) in patients with chronic renal failure (CRF) have been attributed to the development of anti-EPO antibodies. The development and validation of a radioimmunoprecipitation (RIP) assay to detect human anti-EPO antibodies in serum or plasma has been hampered by the lack of purified antibody to fully characterize and validate the assay. We have prepared an affinity-purified human antibody to EPO and used the antibody to characterize and validate a sensitive and reproducible RIP assay that can qualitatively measure anti-EPO antibody in serum or plasma samples. The lower limit of detection of the assay is 8 ng/ml of purified antibody. The threshold for detecting antibody is > or =0.9% cpm bound. The precision of the assay using purified antibody standards ranges from 5.8% to 15.3% and the precision of the assay using dilutions of the positive control ranges from 15.9% to 18.7%. EPO in the samples did not interfere with detection of the anti-EPO antibody except at high concentrations. 相似文献
12.
13.
The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study
下载免费PDF全文
![点击此处可从《Asia-Pacific Journal of Clinical Oncology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Belinda Lee Hui‐Li Wong Mark Tacey Jeanne Tie Rachel Wong Margaret Lee Louise Nott Jeremy Shapiro Ross Jennens Natalie Turner Ben Tran Sumitra Ananda Desmond Yip Gary Richardson Phillip Parente Lionel Lim Greg Stefanou Matthew Burge Mahesh Iddawela Jeremy Power Peter Gibbs 《Asia-Pacific Journal of Clinical Oncology》2017,13(4):314-321
14.
15.
16.
17.
Lim Hui Yin Lui Brandon Tacey Mark Selan Carly Donnan Geoffrey Burrell Louise M. Nandurkar Harshal Ho Prahlad 《Journal of thrombosis and thrombolysis》2021,52(2):610-619
Journal of Thrombosis and Thrombolysis - Global coagulation assays (GCAs) may provide a more comprehensive individual hemostatic profiling. We aim to evaluate GCAs (thromboelastography, thrombin... 相似文献
18.
19.
Karen L. Eskow Jaunarajs PhD David G. Standaert MD PhD Tacey X. Viegas PhD Michael D. Bentley PhD Zhihao Fang MS Bekir Dizman PhD Kunsang Yoon PhD Rebecca Weimer BS Paula Ravenscroft PhD Tom H. Johnston PhD Michael P. Hill PhD Jonathan M. Brotchie PhD Randall W. Moreadith MD PhD 《Movement disorders》2013,28(12):1675-1682
Currently available dopaminergic drugs such as levodopa and dopamine (DA) receptor agonists impart considerable improvement in Parkinson's disease (PD) motor symptoms but often lead to significant motor complications including “wearing‐off” and dyskinesia. Such complications are believed to stem from the pulsatile nature of dopaminergic stimulation with these agents. Continuous dopaminergic drug delivery using polyoxazoline (POZ) polymer conjugation may improve motor symptoms, while avoiding development of side effects. The purposes of the current study are to characterize the in vitro and in vivo pharmacokinetics of POZ conjugation of a U.S. Food and Drug Administration (FDA)‐approved DA agonist, rotigotine, and to evaluate their effects in an established rat model of PD. After determination of release profiles of several POZ‐conjugated constructs (“fast”: SER‐212; “moderate”: SER‐213; and “slow”: SER‐214) using in vitro hydrolysis, normal male Sprague‐Dawley rats were used for determination of the pharmacokinetic profile of both acute and chronic exposure. Finally, a separate group of rats was rendered hemiparkinsonian using intracranial 6‐hydroxydopamine (6‐OHDA) infusions, treated acutely with POZ‐rotigotine, and assessed for rotational behavior and antiparkinsonian benefit using the cylinder test. POZ‐rotigotine formulations SER‐213 and SER‐214 led to substantial pharmacokinetic improvement compared to unconjugated rotigotine. In addition, SER‐214 led to antiparkinsonian effects in DA‐lesioned rats that persisted up to 5 days posttreatment. Repeated weekly dose administration of SER‐214 to normal rats for up to 12 weeks demonstrated highly reproducible pharmacokinetic profiles. The continuous dopaminergic stimulation profile afforded by SER‐214 could represent a significant advance in the treatment of PD, with potential to be a viable, once‐per‐week therapy for PD patients. 相似文献
20.
Smolec J DeSilva B Smith W Weiner R Kelly M Lee B Khan M Tacey R Hill H Celniker A Shah V Bowsher R Mire-Sluis A Findlay JW Saltarelli M Quarmby V Lansky D Dillard R Ullmann M Keller S Karnes HT 《Pharmaceutical research》2005,22(9):1425-1431
The development and validation of ligand binding assays used in the support of pharmacokinetic studies has been the focus of various workshops and publications in recent years, all in an effort to establish a guidance document for standardization of these bioanalytical methods. This summary report of the workshop from 2003 focuses on the issues discussed in presentations and notes points of discussion and areas of consensus among the participants. 相似文献